Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/2/2016 |
| Start Date: | May 2012 |
| End Date: | December 2013 |
| Contact: | Hartmut Malluche, MD |
| Email: | hhmall@uky.edu |
| Phone: | 8593235049 |
Primary objectives: A. To evaluate the effect of Zortress® versus standard immunosuppression
therapy on progression of CAC as evidenced by changes in Agatston scores from baseline and
at 6, and 12 months in renal transplantation patients. B. To investigate progression of CAC
in patients undergoing renal transplantation within the study period.
Secondary objectives:
1. To evaluate in renal transplantation the effect of Zortress® versus standard
immunosuppression therapy on bone mass as evidenced by changes in quantitative computed
tomography (QCT) and dual energy X-ray absorptiometry (DXA).
2. To evaluate in renal transplantation the effect of Zortress® versus standard
immunosuppression therapy on activity of bone forming and resorbing cells as evidenced
by changes in bone histology.
3. To evaluate in renal transplantation the effect of Zortress® versus standard
immunosuppression therapy on biochemical parameters of bone turnover as evidenced by
changes in serum Parathyroid Hormone (PTH), Bone-Specific Alkaline Phosphatase (BSAP),
Tartrate-Resistant Acid Phosphatase (TRAP), Sclerostin, Receptor Activator of Nuclear
factor Kappa B Ligand (RANKL), Osteoprotegerin (OPG), , serum CTX (C-terminal
telopeptide of type 1 collagen), and urinary NTX (N-terminal cross link telopeptide).
4. To evaluate in renal transplantation the effect of Zortress® versus standard
immunosuppression therapy on cardiovascular events, graft rejection and patient
survival.
therapy on progression of CAC as evidenced by changes in Agatston scores from baseline and
at 6, and 12 months in renal transplantation patients. B. To investigate progression of CAC
in patients undergoing renal transplantation within the study period.
Secondary objectives:
1. To evaluate in renal transplantation the effect of Zortress® versus standard
immunosuppression therapy on bone mass as evidenced by changes in quantitative computed
tomography (QCT) and dual energy X-ray absorptiometry (DXA).
2. To evaluate in renal transplantation the effect of Zortress® versus standard
immunosuppression therapy on activity of bone forming and resorbing cells as evidenced
by changes in bone histology.
3. To evaluate in renal transplantation the effect of Zortress® versus standard
immunosuppression therapy on biochemical parameters of bone turnover as evidenced by
changes in serum Parathyroid Hormone (PTH), Bone-Specific Alkaline Phosphatase (BSAP),
Tartrate-Resistant Acid Phosphatase (TRAP), Sclerostin, Receptor Activator of Nuclear
factor Kappa B Ligand (RANKL), Osteoprotegerin (OPG), , serum CTX (C-terminal
telopeptide of type 1 collagen), and urinary NTX (N-terminal cross link telopeptide).
4. To evaluate in renal transplantation the effect of Zortress® versus standard
immunosuppression therapy on cardiovascular events, graft rejection and patient
survival.
Inclusion Criteria:
- De novo renal transplant recipients (from deceased or living donors) between 18-70
years of age
- Willingness to participate in the study and comply with study requirements as
evidenced by signed IRB-approved informed consent
Enrollment Exclusion Criteria:
- Previous solid organ transplant
- Known hypersensitivity to any of the study drugs, or their class, or to any of their
excipients
- Recipients of an investigational drug within 30 days before transplant
- Any abnormal physical or laboratory findings of clinical significance which would
interfere with conduct of the study
- Females of childbearing potential who are planning to become pregnant, who are
pregnant and/or lactating, or unwilling to use medically approved means of
contraception
Randomization Exclusion Criteria:
- Platelet count <75,000/mm
- White blood cell count of < 2,000/mm³
- Hypercholesterolemia (>400 mg/dL) or hypertriglyceridemia (>500 mg/dL) despite
lipid-lowering therapy
- Presence of any clinically significant infection requiring IV antibiotics
- Positive serum HCG (women of childbearing potential)
- Spot urine protein to creatinine ratio (UPr/Cr ) ≥ 0.5
- Any biopsy-confirmed acute rejection since transplant
- Baseline CAC score < 100 at baseline reading
We found this trial at
1
site
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
Click here to add this to my saved trials
